• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Acute thrombosis during left main stenting using tap technique in a patient presenting with non-ST-segment elevation acute coronary syndrome.

作者信息

Natarajan Deepak

出版信息

Cardiovasc Revasc Med. 2015 Jun;16(4):249-53. doi: 10.1016/j.carrev.2014.11.004. Epub 2014 Dec 10.

DOI:10.1016/j.carrev.2014.11.004
PMID:25537732
Abstract

This case reports the sudden development of large burden of thrombi in the left anterior descending coronary artery immediately following distal left main stenting using TAP technique in a middle aged man who presented with non ST-segment elevation acute coronary syndrome despite having been administered 7,500 units of unfractionated heparin and being given 325 mg of aspirin and 60 mg of prasugrel prior to the procedure. The thrombi were managed effectively by giving an intra-coronary high bolus dose of tirofiban (25 mcg/kg) without the need for catheter thrombus extraction. Tirofiban intra-venous infusion was maintained for 18 hours, and the patient was discharged in stable condition on the third day. Importantly there is no controlled study on upstream administration of glycoprotein IIb/IIIa inhibitors in addition to the newer more potent anti-platelet agents in patients with unprotected distal left main disease presenting with non ST-segment elevation acute coronary syndrome, nor is there any data on safety and efficacy of mandatory usage of injectable anti-platelet agents at the start of a procedure in a catheterization laboratory in such a setting.

摘要

相似文献

1
Acute thrombosis during left main stenting using tap technique in a patient presenting with non-ST-segment elevation acute coronary syndrome.
Cardiovasc Revasc Med. 2015 Jun;16(4):249-53. doi: 10.1016/j.carrev.2014.11.004. Epub 2014 Dec 10.
2
Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.在接受经皮冠状动脉介入治疗的心肌梗死患者中,普拉格雷与替罗非班推注与短时间推注后持续输注及与普拉格雷联合应用的比较:FABOLUS PRO 试验(与替罗非班比较,在 ST 段抬高型心肌梗死患者接受负荷剂量普拉格雷治疗的基础上或替代替罗非班通过提前中断或缩短输液管路的方式来实现替格瑞洛的应用)。
JACC Cardiovasc Interv. 2012 Mar;5(3):268-77. doi: 10.1016/j.jcin.2012.01.006.
3
Antiplatelet intervention in acute coronary syndrome.急性冠脉综合征的抗血小板治疗。
Am J Ther. 2009 Sep-Oct;16(5):e29-40. doi: 10.1097/MJT.0b013e31804c7238.
4
Effects of upstream tirofiban versus downstream tirofiban on myocardial damage and 180-day clinical outcomes in high-risk acute coronary syndromes patients undergoing percutaneous coronary interventions.替罗非班上游治疗与下游治疗对高危急性冠状动脉综合征患者行经皮冠状动脉介入治疗后心肌损伤及 180 天临床结局的影响。
Chin Med J (Engl). 2009 Aug 5;122(15):1732-7.
5
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.使用糖蛋白IIb/IIIa抑制剂替罗非班治疗的不稳定型冠状动脉综合征患者早期侵入性策略与保守策略的比较
N Engl J Med. 2001 Jun 21;344(25):1879-87. doi: 10.1056/NEJM200106213442501.
6
The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.血小板糖蛋白IIb/IIIa抑制剂在治疗非ST段抬高型急性冠状动脉综合征高危患者中的新作用。
Curr Med Res Opin. 2007 Jun;23(6):1217-26. doi: 10.1185/030079907X188143. Epub 2007 Apr 23.
7
Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.稳定型和不稳定型冠状动脉疾病经皮冠状动脉介入治疗期间的药物治疗:意大利血管成形术药物评估(IDEA)研究
Ital Heart J. 2005 Feb;6(2):106-18.
8
Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.院前糖蛋白IIb/IIIa抑制剂对ST段抬高型心肌梗死且出血风险高的患者的净临床获益:使用CRUSADE出血评分评估替罗非班对出血高风险患者的影响
J Invasive Cardiol. 2012 Mar;24(3):84-9.
9
An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.一种预测替罗非班在非ST段抬高型急性冠状动脉综合征中获益的综合临床方法。TIMI非稳定性心绞痛/非ST段抬高型心肌梗死风险评分在PRISM-PLUS研究中的应用。
Eur Heart J. 2002 Feb;23(3):223-9. doi: 10.1053/euhj.2001.2738.
10
Successful use of glycoprotein IIb/IIIa inhibitor, heparin, and IABP during PCI in a post-neurosurgical patient with STEMI and cardiogenic shock due to very late bare-metal stent thrombosis.在一名因极晚期裸金属支架血栓形成导致ST段抬高型心肌梗死和心源性休克的神经外科术后患者进行经皮冠状动脉介入治疗(PCI)期间,成功使用糖蛋白IIb/IIIa抑制剂、肝素和主动脉内球囊反搏(IABP)。
J Invasive Cardiol. 2012 Feb;24(2):76-8.

引用本文的文献

1
Engineering Factor Xa Inhibitor with Multiple Platelet-Binding Sites Facilitates its Platelet Targeting.工程化具有多个血小板结合位点的因子 Xa 抑制剂可促进其血小板靶向性。
Sci Rep. 2016 Jul 19;6:29895. doi: 10.1038/srep29895.